Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“Excited for the positive news on PFS for Destiny 09.
Any predictions on HR for PFS? ( my bet is on close to 0.5 for combination of Enhertu plus Pertuzumab)
The press release focuses on Enhertu plus Pertuzumab vs THP. Eagerly awaiting the complete dataset.”
